We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Home » Jennerex Presents Positive Clinical Data From Phase II Trial of JX-594 in Sorafenib-Refractory Liver Cancer Patients
Jennerex Presents Positive Clinical Data From Phase II Trial of JX-594 in Sorafenib-Refractory Liver Cancer Patients
September 17, 2012
Jennerex presented Phase II clinical data of JX-594 delivered first intravenously and subsequently through intra-tumoral route demonstrating safety as well as disease control and tumor responses in patients with hepatocellular carcinoma. Yahoo! Finance
